Sarepta Therapeutics, Inc. (SRPT) stock
Close on Nov 11, 2026Market cap $1.76BP/E –Yield –
Sarepta Therapeutics, Inc. saw revenue fall 18.9% to $1.96B over the twelve months to Sep 30, 2026. Free cash flow was $176.40M. At the latest close the market valued the company at $1.76B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.76B
- P/E ratio
- –
- Price to sales
- 0.90
- Price to book
- 1.15
- Dividend yield
- –
- Free cash flow yield
- 10.01%
Fundamentals
- Revenue
- $1.96B
- Net income
- -$114.62M
- EPS, diluted
- -$1.37
- Free cash flow
- $176.40M
- Book value per share
- $14.43
- Diluted shares
- 106M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $16.42
- Open
- $16.50
- Day's range
- $16.16 – $16.78
- Volume
- 2,056,143
- Average volume (20 days)
- 2,398,439
- Index membership
- S&P SmallCap 600 (since Nov 2025), Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.00
- 52-week range
- $14.68 – $24.68
- RSI (14 days)
- 40.3
- Volatility (1 year)
- 70.6%
- Relative volume
- 0.71×
- WACC
- 9.5%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SRPT | S&P 500 | Difference | SRPT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.6% | -2.4% | −4.1 pts | ||
| 3 months | -8.5% | -1.2% | −7.3 pts | ||
| Year to date | -22.5% | +12.3% | −34.8 pts | ||
| 1 year | -7.2% | +12.4% | −19.7 pts | ||
| 3 years | -79.0% | +78.8% | −157.8 pts | -40.6% | +21.4% |
| 5 years | -80.6% | +75.2% | −155.8 pts | -28.0% | +11.9% |
| 10 years | -57.8% | +311.1% | −368.9 pts | -8.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sarepta Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Sarepta Therapeutics
Pharmaceutical Preparations
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovering and developing precision genetic medicines for rare diseases. The company specializes in RNA-targeted therapeutics, siRNA knockdown therapies, and gene therapies, primarily addressing neuromuscular conditions such as Duchenne muscular dystrophy. Its commercial product portfolio includes multiple exon-skipping therapies—EXONDYS 51, VYONDYS 53, and AMONDYS 45—as well as the gene therapy ELEVIDYS. Sarepta develops its therapeutic pipeline independently and in partnership with strategic collaborators like Arrowhead and Roche. The company's customer base consists of patients requiring specialized treatments, with products supplied through home infusion specialty pharmacies, specialty distributors, hospitals, and hospital outpatient clinics.
Company profile, executives and historySarepta Therapeutics stock: common questions
What is Sarepta Therapeutics's stock price?
SRPT closed at $16.68 on Nov 11, 2026, up 1.58% on the day. Over the past 52 weeks it traded between $14.68 and $24.68.
What is Sarepta Therapeutics's market cap?
Sarepta Therapeutics was worth $1.76B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SRPT's P/E ratio?
Sarepta Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.37), so it has no meaningful P/E ratio.
How much revenue does Sarepta Therapeutics make?
Sarepta Therapeutics reported revenue of $1.96B for the twelve months to Sep 30, 2026, down 18.9% from a year earlier.
Does Sarepta Therapeutics pay a dividend?
No. Sarepta Therapeutics has not paid a cash dividend over the last twelve months.
When does Sarepta Therapeutics report earnings next?
Sarepta Therapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has SRPT stock performed over the past year?
Including dividends, SRPT returned -7.2% over the past year, against +12.4% for the S&P 500.
How many SRPT shares are sold short?
19M shares were sold short at the latest FINRA report, 19.41% of the float, or 7.8 days of average trading volume.
Who are Sarepta Therapeutics's competitors?
Companies most similar to Sarepta Therapeutics by business, industry and size include PTCT, BBIO, INSM, IONS, BMRN.
See a number that looks wrong?